Apellis Pharmaceuticals Inc (APLS) - Total Liabilities

Latest as of March 2026: $667.61 Million USD

Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has total liabilities worth $667.61 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Apellis Pharmaceuticals Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Apellis Pharmaceuticals Inc - Total Liabilities Trend (2013–2025)

This chart illustrates how Apellis Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Apellis Pharmaceuticals Inc's balance sheet.

Apellis Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Citra Putra Realty Tbk PT JK:CLAY	Indonesia	Rp529.29 Billion
ARTRYA Ltd AU:AYA	Australia	AU$2.84 Million
Vietnam Construction and Import Export JSC VN:VCG	Vietnam	₫15.47 Trillion
Paslin Digital Technology Co Ltd SHG:600215	China	CN¥1.32 Billion
Shenzhen TVT Digital Technology Co Ltd SHE:002835	China	CN¥429.93 Million
Jinsanjiang (Zhaoqing) Silicon Material Company Limited SHE:301059	China	CN¥127.38 Million
Xerox Corp NASDAQ:XRX	USA	$9.17 Billion
Shandong Hiking International Co Ltd Class A SHG:600735	China	CN¥427.87 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Apellis Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Apellis Pharmaceuticals Inc net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.63	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.61	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.62	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Apellis Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Apellis Pharmaceuticals Inc (2013–2025)

The table below shows the annual total liabilities of Apellis Pharmaceuticals Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	$705.11 Million	+7.40%
2024-12-31	$656.51 Million	+10.49%
2023-12-31	$594.21 Million	+0.65%
2022-12-31	$590.35 Million	-13.58%
2021-12-31	$683.10 Million	-9.64%
2020-12-31	$756.01 Million	+112.95%
2019-12-31	$355.02 Million	+734.13%
2018-12-31	$42.56 Million	+28.24%
2017-12-31	$33.19 Million	+812.04%
2016-12-31	$3.64 Million	+13.71%
2015-12-31	$3.20 Million	+195.89%
2014-12-31	$1.08 Million	+59.76%
2013-12-31	$676.96K	--

About Apellis Pharmaceuticals Inc

NASDAQ:APLS USA Biotechnology

Market Cap

$412.48 Million

Market Cap Rank

#13337 Global

#3233 in USA

Share Price

$3.22

Change (1 day)

+3.29%

52-Week Range

$3.05 - $41.12

All Time High

$93.31